Keyphrases
Atrial Fibrillation
84%
Anticoagulants
66%
Non-valvular Atrial Fibrillation
41%
New-onset Atrial Fibrillation
39%
Vitamin K Antagonists
37%
Confidence Interval
34%
Systemic Embolism
33%
Tuberculous Pericarditis
27%
GARFIELD
27%
Newly Diagnosed
26%
Fibrillation
23%
1-year Outcome
23%
Major Bleeding
23%
Stroke Prevention
23%
Stroke Risk
22%
Hazard Ratio
21%
Black African
20%
Rheumatic Heart Disease
20%
All-cause Mortality
20%
Antithrombotic Therapy
19%
Anticoagulation
18%
Antiplatelet
18%
South Africa
16%
Risk Profile
16%
Treatment Patterns
16%
Non-vitamin K Antagonist Oral Anticoagulants
15%
Africa
14%
Therapeutic Range
14%
Bleeding
14%
GARFIELD-AF
14%
Sub-Saharan Africa
14%
High Risk
14%
Disease Registry
13%
Multicenter Trial
13%
2-year Outcome
13%
Prednisolone
13%
Pericarditis
13%
Warfarin
13%
Placebo
13%
Hypertension
12%
Antiplatelet Monotherapy
12%
International Normalized Ratio
12%
Clinical Outcomes
12%
Congestive Heart Failure
11%
2-year Follow-up
11%
Anticoagulant Therapy
10%
Baseline Characteristics
10%
Anticoagulant Treatment
10%
Chronic Kidney Disease
9%
Patient Management
9%
Medicine and Dentistry
Atrial Fibrillation
100%
Apoplexy
62%
Antithrombotic
49%
Vitamin K Antagonist
35%
Antiplatelet
28%
Fibrillation
22%
Anticoagulation
22%
Hazard Ratio
21%
Tuberculous Pericarditis
20%
Rheumatic Heart Disease
20%
Congestive Heart Failure
19%
Major Bleeding
18%
All Cause Mortality
14%
Anticoagulant Therapy
12%
Monotherapy
11%
Observational Study
9%
Chronic Kidney Disease
9%
Antithrombotic Therapy
8%
Ciclonicate
8%
Human Immunodeficiency Virus
8%
Anticoagulant
7%
CHA2DS2-VASc Score
7%
Mycobacterium Indicus Pranii
6%
Pericarditis
6%
Prednisolone
6%
Placebo
6%
Diabetic Hypertension
6%
Pacemaker Implantation
6%
Heart Pacing
6%
Arrhythmia
6%
Nonischemic Cardiomyopathy
6%
Cardioversion
6%
Heart Valve Prosthesis
6%
Warfarin
6%
Mechanical Heart Valve
6%
Randomized Controlled Trial
6%
Ejection Fraction
6%
Diabetes Mellitus
6%
Systolic Blood Pressure
6%
Self Concept
6%
Low and Middle Income Countries
6%
Implant
6%
Risk Stratification
6%
Retrospective Study
6%
Electrocardiogram
6%
Blood Pressure
6%
Myocardial Disease
6%
Antihypertensive Agent
6%
Vascular Disease
6%
Tamponade
6%
